Consider a biotechnology firm, which has no cash flow-producing assets currently but has one product in the pipeline that has much promise in providing a treatment for diabetes. The product has not been approved by the FDA, and, even if approved, it could be faced with competition from similar products being worked on by other firms. The firm, however, would hold the patent rights to this product for the next 25 years. After a series of simulations, under a variety of technological and competitive environments, the expected present value of the cash inflows from selling the product is estimated to be $500 million with a variance of 0.20 (signifying the uncertainty of the process). The expected present value of the cost of developing is estimated to be $400 million. The annual cash flows on the product, once developed, are expected to be 4% of the present value of the inflows. The 25-year bond rate is 7.0%. Using the Black-Scholes option model pricing, calculate the value of the firm. (TIP: watch for the dividend yield) show your calculations (d1, d2, N(d1), N(d2) and the value of the call.